Dragon Pharmaceutical Inc.

Dragon Pharmaceutical Inc. manufactures and distributes pharmaceutical products in the China and internationally. The company operates through two divisions, Penicillin and Cephalosporin. The Penicillin division engages in the production and sale of cefalexin, a Penicillin G downstream product for the treatment of urinary tract infections, respiratory tract infections, and skin and soft tissue infections; cefadroxil, a Penicillin G downstream product for the treatment of mild to moderate susceptible infections, such as strep throat, and skin and urinary tract infections; and clavulanic acid. The Cephalosporin division involves in the production and sale of 7-ACA, a core intermediate for downstream cephalosporin antibiotics; active pharmaceutical ingredients (API); and cephalosporin formulated finished drugs. Its products include ceftazidime that is used in treating infections related to respiratory tract, skin, urinary and genital tracts, septicemia, abdominal cavity, and central nervous system; Cefuroxime for the treatment of bacterial infections of the middle ear, tonsillitis, throat infections, laryngitis, bronchitis, and pneumonia; Cefotaxime; Ceftriaxone for the treatment of community-acquired or mild to moderate health care-associated pneumonia; Cefalotin for preventing bacteria from forming an adequate and protective cell wall; and cephalosporin formulated powder for injection. The company sells its formulated finished products to regional distributors; and bulk pharmaceutical intermediate and API products to pharmaceutical companies. Dragon Pharmaceutical Inc. was formerly known as First Geneva Investments, Inc. and changed its name to Dragon Pharmaceutical Inc. in September, 1998. The company was founded in 1989 and is based in Vancouver, Canada.